These results complement those of the AMLSG 16-10 trial, which demonstrated improved event-free survival for patients with FLT3-ITD AML who received pretransplant midostaurin and began midostaurin within 100 days post-transplant compared with patients who only received pretransplant midostaurin [17]. The gene discussed is FLT3; the disease is acute myeloid leukemia.